Table 2. Detailed clinical characteristics of the 6 patients with high-level MET copy number treated with crizotinib.
| Patient number | Age (years) | Gender | Lung cancer subtype | Clinical stage | Absolute MET CN | MaxMAF or tumor cell percentage# | Adjusted MET CN | Previous lines of treatment | MET TKI administered | PFS (days) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 36 | M | Adenocarcinoma | IV | 11.65 | 41.24% | 13.70 | 2 (1 line chemotherapy, 1 line immunotherapy) | Crizotinib | 117* |
| 2 | 61 | M | Adenocarcinoma | IV | 13.33 | 47.15% | 14.01 | 1 (chemotherapy) | Crizotinib | 89 |
| 3 | 63 | M | Adenocarcinoma | IV | 4.56 | 20%# | 14.80 | 0 | Crizotinib | 58* |
| 4 | 65 | M | Undetermined | IV | 8.82 | 14.48% | 25.55 | 0 | Crizotinib | 269* |
| 5 | 51 | M | Adenocarcinoma | IV | 9.30 | 14.40% | 27.35 | 1 (chemotherapy) | Crizotinib | 744* |
| 6 | 60 | M | Adenocarcinoma | IIIb | 3.36 | 3%# | 47.33 | 0 | Crizotinib | 143* |
#, the hash indicates the tumor cell percentage was used for the normalization of the sample; *, patients whose disease had not progressed as of last follow-up, PFS indicate the day of last follow-up. MET, mesenchymal-epithelial transition factor; CN, copy number; TKI, tyrosine kinase inhibitor; PFS, progression-free survival.